News

Syndax’s entinostat is an oral, highly selective histone deacetylase (HDAC) inhibitor, while Keytruda is Merck’s first anti-PD-1 therapy approved in the US. Keytruda is a humanized monoclonal antibody

The approval will allow the company to expand its Phase II OCCC trial currently underway in multiple centers in North America with Princess Margaret Cancer Centre in Canada

Aduro is focused on the discovery and development of next generation cancer immunotherapies targeting the Stimulator of Interferon Genes (STING) pathway. The Swiss firm has also launched a

The deal advances Merck Serono’s science-driven strategy to develop new therapies that modulate the immune system’s natural ability to fight tumors. As part of the deal, Intrexon will

Under the deal, the Irish firm has offered to pay $46 a share for Hyperion, representing a 35% premium to the volume weighted average price for its shares

The deal provides regional packaging capabilities and complements Catalent’s existing facility in Braeside, Victoria, where it produces oral dose products including softgels, Vegicaps capsules, and OptiShell capsules, for

The Irish firm will pay $101 per share to acquire Auspex’s portfolio of new medicines for people who live with movement disorders. The boards of directors from both

Following approval, the new therapy will be marketed under the name Synjardy in Europe. The single-pill therapy is a combination of the sodium glucose cotransporter 2 (SGLT2) inhibitor,

FOLFOX is a combination of the drugs folinic acid, 5-fluorouracil and oxaliplatin. A total of 173 patients were included in the trial, which was conducted at about 30